NASDAQ:NVIV - Invivo Therapeutics Stock Price, Forecast & News

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Invivo Therapeutics's stock reverse split before market open on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($224.40) EPS for the quarter, missing the Zacks' consensus estimate of ($12.30) by $212.10. View Invivo Therapeutics' Earnings History.

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Invivo Therapeutics.

Press coverage about NVIV stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Invivo Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the immediate future. View News Stories for Invivo Therapeutics.

Some companies that are related to Invivo Therapeutics include Obalon Therapeutics (OBLN), Lianluo Smart (LLIT), Hancock Jaffe Laboratories (HJLI), Atossa Genetics (ATOS), Avinger (AVGR), Dynatronics (DYNT), PlusTherapeuticsInc . (PSTV), Encision (ECIA), CELLECT BIOTECH/S (APOP), Neurometrix (NURO), AdvanSource Biomaterials Corpration (ASNB), Regenicin (RGIN), Cytocore (MDIT), Nuvectra (NVTR) and Valeritas (VLRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Invivo Therapeutics investors own include Anavex Life Sciences (AVXL), iShares US Preferred Stock ETF (PFF), Gilead Sciences (GILD), Verastem (VSTM), Flexion Therapeutics (FLXN), Apollo Investment (AINV), Ophthotech (OPHT), TrovaGene (TROV), Actinium Pharmaceuticals (ATNM) and NovaBay Pharmaceuticals (NBY).

Invivo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (6.81%) and Renaissance Technologies LLC (4.46%). View Institutional Ownership Trends for Invivo Therapeutics.

NVIV stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Invivo Therapeutics.

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVIV stock can currently be purchased for approximately $6.86.

Invivo Therapeutics has a market capitalization of $3.77 million. The biotechnology company earns $-23,420,000.00 in net income (profit) each year or ($67.57) on an earnings per share basis. Invivo Therapeutics employs 6 workers across the globe.View Additional Information About Invivo Therapeutics.

The official website for Invivo Therapeutics is http://www.invivotherapeutics.com/.

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]